Please login to the form below

Not currently logged in
Email:
Password:

companion diagnostics

This page shows the latest companion diagnostics news and features for those working in and with pharma, biotech and healthcare.

Roche agrees $2.4bn takeover of genomics player Foundation

Roche agrees $2.4bn takeover of genomics player Foundation

Prior to the approval of F1CDx, most companion diagnostics for cancer matched one test to one drug, but the FDA said that using Foundation’s test could identify which patients with ... There has also been movement at the federal level in the US, with

Latest news

  • Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more

    Foundation Medicine is a major player in the emerging field of next generation cancer diagnostics and genomic profiling, and two developments yesterday confirmed it as a leader in what will undoubtedly ... If approved, this test could be the

  • EMA starts firming up its stance on personalised medicines EMA starts firming up its stance on personalised medicines

    New draft European guidelines on personalised medicines and companion diagnostics are expected to be released by December 2018. ... The European Medicines Agency (EMA) hopes that when finalised they will help optimise the co-development of medicines and

  • Focus on value: A prescription for pharma Focus on value: A prescription for pharma

    In the long run, companion diagnostics will enable targeting the patients most likely to benefit from a particular therapy.

  • A butterfly flaps its wings A butterfly flaps its wings

    Firstly, deciding rationally who and when it is sensible to treat will be difficult and that creates opportunities for everything from diagnostics to data analytics. ... Secondly, in a world where bang for bucks is everything, single technology

  • Clinical trials enter the genomic age Clinical trials enter the genomic age

    And the same factors are particularly important when it comes to companion diagnostics products. ... The increasing use of molecular drugs targeting specific genomic profiles goes hand-in-hand with the co-development of companion diagnostics in the drug

More from news
Approximately 3 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Breakthrough innovation Breakthrough innovation

    Many pharmaceutical companies are increasingly looking to innovate through the development of companion diagnostics and drug delivery devices, and/or services such as patient monitoring and adherence support. ... An optimal innovation approach. Creating

  • Choosing destiny Choosing destiny

    immuno-oncology and companion diagnostics.

  • Harnessing complexity Harnessing complexity

    Harnessing complexity. Companion diagnostics in oncology. As an increasing number of drugs gain approval for patients whose cancers have certain molecular characteristics, the promise of truly personalised medicine is edging closer ... This delicate

  • Harnessing the power of genetics Harnessing the power of genetics

    Effective use relies on the availability of clinical grade, affordable companion diagnostics in major therapy centres.

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    Relationships with pharma. This changing role can be seen with the increase in the number of companion diagnostics approved alongside important new drugs, including Roche's FDA approval for Tarceva in ... lung cancer, which was backed together with Roche

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Dr Holger Adelmann joins DIA EMEA Dr Holger Adelmann joins DIA EMEA

    In that role he oversaw the reengineering of its clinical biomarker and companion diagnostics business to align with upcoming portfolio demands.

  • FlowMetric Diagnostics names president FlowMetric Diagnostics names president

    FlowMetric Diagnostics names president. Amy Williams has over 25 years of experience in life sciences. ... It is a great time for the development of new flow cytometry-based companion diagnostics which can help advance personalised medicine and better

  • Roche appoints new oncology research head Roche appoints new oncology research head

    Commenting on Pao's appointment, Reed said: "William is recognised as one of the world's leading molecular oncologists, with world class expertise in targeted cancer therapeutics, translational medicine, molecular diagnostics, ... diagnostics company,

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Excellence in oncology: Developing an effective biomarker strategy

    Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers, physicians and patients.

  • Research Partnership

    Medical devices and diagnostics. Our experience covers everything from insulin pens to large-scale surgical systems. ... Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers, physicians and

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics